Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
ONC Quote, Financials, Valuation and Earnings
Last price:
$311.96
Seasonality move
:
12.25%
Day range:
$308.16 - $314.46
52-week range:
$172.67 - $385.22
Dividend yield:
0%
P/E ratio:
599.83x
P/S ratio:
6.96x
P/B ratio:
9.08x
Volume:
128.1K
Avg. volume:
319.5K
1-year change:
71.64%
Market cap:
$34.5B
Revenue:
$3.8B
EPS (TTM):
$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $400.06 |
|
ACIU
AC Immune SA
|
$994.8K | -$0.22 | 18.61% | -6.92% | $9.01 |
|
ADXN
Addex Therapeutics Ltd.
|
$242.8K | -- | 2.35% | -- | $30.00 |
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.17% | 106.38% | $213.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$311.73 | $400.06 | $34.5B | 599.83x | $0.00 | 0% | 6.96x |
|
ACIU
AC Immune SA
|
$3.12 | $9.01 | $313.9M | -- | $0.00 | 0% | 60.84x |
|
ADXN
Addex Therapeutics Ltd.
|
$8.89 | $30.00 | $11M | 0.77x | $0.00 | 0% | 40.66x |
|
CRSP
CRISPR Therapeutics AG
|
$56.71 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.35x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$170.80 | $213.00 | $10.4B | 15.09x | $0.00 | 0% | 2.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
|
ACIU
AC Immune SA
|
6.95% | 3.999 | 2.01% | 1.10x |
|
ADXN
Addex Therapeutics Ltd.
|
0.61% | 2.172 | 0.5% | 1.91x |
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
ADXN
Addex Therapeutics Ltd.
|
-- | -$869.9K | -73.49% | -73.84% | -1403.07% | -$687.4K |
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
BeOne Medicines Ltd. vs. Competitors
-
Which has Higher Returns ONC or ACIU?
AC Immune SA has a net margin of 8.84% compared to BeOne Medicines Ltd.'s net margin of -1688.87%. BeOne Medicines Ltd.'s return on equity of 1.92% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.83.86% $1.09 $6B ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About ONC or ACIU?
BeOne Medicines Ltd. has a consensus price target of $400.06, signalling upside risk potential of 28.34%. On the other hand AC Immune SA has an analysts' consensus of $9.01 which suggests that it could grow by 186.4%. Given that AC Immune SA has higher upside potential than BeOne Medicines Ltd., analysts believe AC Immune SA is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.18 1 1 ACIUAC Immune SA4 0 0 -
Is ONC or ACIU More Risky?
BeOne Medicines Ltd. has a beta of 0.452, which suggesting that the stock is 54.771% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.243%.
-
Which is a Better Dividend Stock ONC or ACIU?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or ACIU?
BeOne Medicines Ltd. quarterly revenues are $1.4B, which are larger than AC Immune SA quarterly revenues of $1.2M. BeOne Medicines Ltd.'s net income of $125M is higher than AC Immune SA's net income of -$19.8M. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 599.83x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.96x versus 60.84x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M ACIUAC Immune SA60.84x -- $1.2M -$19.8M
-
Which has Higher Returns ONC or ADXN?
Addex Therapeutics Ltd. has a net margin of 8.84% compared to BeOne Medicines Ltd.'s net margin of -3178.71%. BeOne Medicines Ltd.'s return on equity of 1.92% beat Addex Therapeutics Ltd.'s return on equity of -73.84%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.83.86% $1.09 $6B ADXNAddex Therapeutics Ltd.-- -$2.10 $7.5M -
What do Analysts Say About ONC or ADXN?
BeOne Medicines Ltd. has a consensus price target of $400.06, signalling upside risk potential of 28.34%. On the other hand Addex Therapeutics Ltd. has an analysts' consensus of $30.00 which suggests that it could grow by 258%. Given that Addex Therapeutics Ltd. has higher upside potential than BeOne Medicines Ltd., analysts believe Addex Therapeutics Ltd. is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.18 1 1 ADXNAddex Therapeutics Ltd.0 0 0 -
Is ONC or ADXN More Risky?
BeOne Medicines Ltd. has a beta of 0.452, which suggesting that the stock is 54.771% less volatile than S&P 500. In comparison Addex Therapeutics Ltd. has a beta of 1.573, suggesting its more volatile than the S&P 500 by 57.32%.
-
Which is a Better Dividend Stock ONC or ADXN?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. Addex Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or ADXN?
BeOne Medicines Ltd. quarterly revenues are $1.4B, which are larger than Addex Therapeutics Ltd. quarterly revenues of $62K. BeOne Medicines Ltd.'s net income of $125M is higher than Addex Therapeutics Ltd.'s net income of -$2M. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 599.83x while Addex Therapeutics Ltd.'s PE ratio is 0.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.96x versus 40.66x for Addex Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M ADXNAddex Therapeutics Ltd.40.66x 0.77x $62K -$2M
-
Which has Higher Returns ONC or CRSP?
CRISPR Therapeutics AG has a net margin of 8.84% compared to BeOne Medicines Ltd.'s net margin of -11973.12%. BeOne Medicines Ltd.'s return on equity of 1.92% beat CRISPR Therapeutics AG's return on equity of -26.17%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.83.86% $1.09 $6B CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B -
What do Analysts Say About ONC or CRSP?
BeOne Medicines Ltd. has a consensus price target of $400.06, signalling upside risk potential of 28.34%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.33 which suggests that it could grow by 43.42%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines Ltd., analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.18 1 1 CRSPCRISPR Therapeutics AG12 10 1 -
Is ONC or CRSP More Risky?
BeOne Medicines Ltd. has a beta of 0.452, which suggesting that the stock is 54.771% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.738, suggesting its more volatile than the S&P 500 by 73.75%.
-
Which is a Better Dividend Stock ONC or CRSP?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or CRSP?
BeOne Medicines Ltd. quarterly revenues are $1.4B, which are larger than CRISPR Therapeutics AG quarterly revenues of $889K. BeOne Medicines Ltd.'s net income of $125M is higher than CRISPR Therapeutics AG's net income of -$106.4M. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 599.83x while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.96x versus 129.35x for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M
-
Which has Higher Returns ONC or JAZZ?
Jazz Pharmaceuticals Plc has a net margin of 8.84% compared to BeOne Medicines Ltd.'s net margin of 22.33%. BeOne Medicines Ltd.'s return on equity of 1.92% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.
Company Gross Margin Earnings Per Share Invested Capital ONCBeOne Medicines Ltd.83.86% $1.09 $6B JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B -
What do Analysts Say About ONC or JAZZ?
BeOne Medicines Ltd. has a consensus price target of $400.06, signalling upside risk potential of 28.34%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 24.71%. Given that BeOne Medicines Ltd. has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe BeOne Medicines Ltd. is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings ONCBeOne Medicines Ltd.18 1 1 JAZZJazz Pharmaceuticals Plc10 2 0 -
Is ONC or JAZZ More Risky?
BeOne Medicines Ltd. has a beta of 0.452, which suggesting that the stock is 54.771% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.
-
Which is a Better Dividend Stock ONC or JAZZ?
BeOne Medicines Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BeOne Medicines Ltd. pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONC or JAZZ?
BeOne Medicines Ltd. quarterly revenues are $1.4B, which are larger than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. BeOne Medicines Ltd.'s net income of $125M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, BeOne Medicines Ltd.'s price-to-earnings ratio is 599.83x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BeOne Medicines Ltd. is 6.96x versus 2.51x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
56
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
